ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amylin Sues Lilly Over Drug Alliance

by Rick Mullin
May 23, 2011 | APPEARED IN VOLUME 89, ISSUE 21

Amylin Pharmaceuticals has filed a lawsuit against Eli Lilly & Co. alleging that Lilly’s new diabetes collaboration with Boehringer Ingelheim violates a 2002 agreement to develop Byetta, Amylin’s diabetes drug. Lilly rejects the allegation that its pact with Boehringer to develop Tradjenta, an oral diabetes drug, constitutes a breach of the Byetta contract. “Our broad marketing experience teaches us that injectables like Byetta generally compete with other injectable treatments in the class rather than with oral antidiabetic agents,” Lilly says. Amylin, which is seeking to block the Boehringer deal, says it intends to continue collaborating with Lilly on Byetta.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment